Pharma tax hike on drug ads—but no guarantee prices fall
S. 1785 — No Handouts for Drug Advertisements Act · Filed by Josh Hawley (R-MO) · 2 cosponsors · Introduced May 15, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends the tax code to prohibit pharmaceutical companies and drug manufacturers from deducting the cost of direct-to-consumer advertising (TV, radio, digital, billboards, direct mail) as a business expense. The ban applies to prescription drugs and compounded medications but excludes ads in medical journals. Companies can no longer reduce their taxable income by the amount they spend advertising drugs directly to the public.
Why we flagged it
The bill is a targeted tax provision that increases the tax burden on pharmaceutical manufacturers by disallowing a specific business deduction. It is not a price control, advertising ban, or consumer protection—it is a revenue-raising measure that uses tax policy to discourage a commercial practice.
What the text implies
- The bill does not ban direct-to-consumer advertising; it only removes the tax deduction. Companies can still advertise at full cost—the tax increase may be passed to consumers through higher drug prices rather than reducing advertising spend.
- Compounded drugs (made under FDA sections 503A and 503B) are included, which may affect small pharmacies and outsourcing facilities that compound medications, not just large pharmaceutical manufacturers.
- The exception for journal advertising preserves a deduction for ads in medical publications, which may be read as favoring physician-targeted marketing over consumer-targeted marketing.
- No appropriation or enforcement mechanism is specified; the IRS must detect and disallow these deductions through normal audit procedures, which may be inconsistently applied.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill imposes a tax cost on pharmaceutical companies, which may reduce their incentive to spend on direct-to-consumer advertising and could theoretically lower drug prices or reduce marketing-driven demand. However, the bill does not cap drug prices, regulate advertising content, or guarantee any public benefit—companies may simply absorb the tax cost or pass it to consumers through higher prices. The civic gain (reduced manipulative marketing) is real but speculative; the tax mechanism is in
Named in the bill
Internal Revenue Service (IRS), Pharmaceutical manufacturers, Prescription drug sponsors, Outsourcing facilities, FDA (referenced for drug definitions)
Where it stands
2 cosponsors: 2 Democrats.
- May 15, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- May 15, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
5 lobbying clients named this bill on 22 disclosure filings across 7 quarters, Mar 2025 to Sep 2026. Those filings disclosed $10,380,000 in lobbying spend. A filing names 20 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 74% of bills with at least one filing.
Josh Hawley, the sponsor, reported $71,000 in PAC receipts in the 2026 cycle.
- CVS Health (and Subsidiaries) — $9,550,000 on 4 filings
- The Campaign for Sustainable Rx Pricing — $450,000 on 5 filings
- Campaign for Sustainable Drug Pricing (csrxp) — $250,000 on 5 filings
- Massachusetts Medical Society — $130,000 on 2 filings
- Coalition for Healthcare Communications — $0 on 6 filings
Lobbying Disclosure Act filings through Oct 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (2,434 characters) on Nov 13, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Mar 2025 to Sep 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Oct 20, 2026 · page rendered 2026-11-22.
“Pharma tax hike on drug ads—but no guarantee prices fall” QuorumCivic. https://share.quorumcivic.app/bill/119/s1785 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.